Table of Contents The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns. TATA India Pharma & Healthcare Fund is a Equity - Sectoral fund launched on 28 Dec 15. It is a fund with High risk and has given a Below is the key information for TATA India Pharma & Healthcare Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis TATA India PHARMA & Healthcare Fund - G
Scheme Objective
CAGR return of -0.2% since its launch. Return for 2019 was 5.5% , 2018 was -2.6% and 2017 was 4.7% . NAV as on 25 Feb 20 ₹9.9094 ↓ -0.15 (-1.52 %) Net Assets (AUM) as on 31 Jan 2020 ₹167 Cr. Launch Date 28 Dec 2015 Category Equity - Sectoral Rating Type Open Ended Fund Risk High AMC Tata Asset Management Limited Alpha Ratio 11.9 Expense Ratio 2.61 % Sharpe Ratio 0.667 Information Ratio 1.11 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹500 Exit Load 0-3 Months (0.25%),3 Months and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 25 Feb 20 Duration Returns 1 Month 3.3% 3 Month 6.3% 6 Month 14.8% 1 Year 16.3% 3 Year 3.4% 5 Year 10 Year 15 Year Since launch -0.2% Historical Annual Returns
Year Returns 2019 5.5% 2018 -2.6% 2017 4.7% 2016 -14.7% 2015 2014 2013 2012 2011 Growth of 10k Over Years
Date Value 31 Jan 16 ₹10,076 31 Jan 17 ₹8,582 31 Jan 18 ₹8,947 31 Jan 19 ₹8,701 31 Jan 20 ₹9,584 
Asset Allocation
Asset Class Value Cash 1.62% Equity 98.44% 
Sector Allocation
Sector Value Health Care 98.44% 
Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 18 | 50012414% ₹24 Cr 77,500
↓ -11,000 Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Jan 16 | SUNPHARMA12% ₹20 Cr 466,100 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB10% ₹16 Cr 83,000
↓ -7,300 Abbott India Ltd (Healthcare)
Equity, Since 31 Oct 16 | 5004889% ₹16 Cr 12,500 Lupin Ltd (Healthcare)
Equity, Since 30 Nov 17 | 5002579% ₹15 Cr 210,000 Ipca Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 16 | 5244947% ₹12 Cr 95,000 Procter & Gamble Health Ltd (Healthcare)
Equity, Since 31 Jul 18 | 5001267% ₹12 Cr 26,000 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 31 Dec 16 | APOLLOHOSP6% ₹10 Cr 62,000 Alembic Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Mar 17 | 5335735% ₹8 Cr 130,000
↓ -14,823 Aurobindo Pharma Ltd (Healthcare)
Equity, Since 31 Jan 17 | AUROPHARMA5% ₹8 Cr 165,000
Talk to our investment specialistFund Managers
Name Since Tenure Sailesh Jain 9 Nov 18 1.06 Yr. Meeta Shetty 9 Nov 18 1.06 Yr. Custodians
Company Address Deutsche Bank AG Deutsche Bank AG,Kodak House, 22, D.N. Road, Registrar & Transfer Agent
Computer Age Management Svcs Address New No.10, Old No.178,,Kodambakkam High Road,,Opp. Hotel Palmgrove,,Nungambakkam FAX 91-44-28283610 Email enq_L@camsonline.com Administrator Companies
Company Address Tata Mutual Fund 1903, B-Wing, Parinee Crescenzo,,G-Block, Bandra Kurla Complex, Bandra East Mumbai 400051 Auditors
Company Address Deloitte Haskins & Sells 12, Dr. Annie Besant Road, Opp. Shiv Sagar Estate,,Worli M/s BSR & Co. KPMG House, Kamala Mills Compound,448 Senapati Bapat Marg,Lower Parel All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year TATA India Pharma & Healthcare Fund
Normal Dividend, Reinvestment ₹9.9094
↓ -0.15 14.8 % 16.3 % 3.39 % - TATA India Pharma & Healthcare Fund
Normal Dividend, Payout ₹9.9094
↓ -0.15 14.8 % 16.3 % 3.39 % - TATA India Pharma & Healthcare Fund
Growth ₹9.9094
↓ -0.15 14.8 % 16.3 % 3.39 % - Data as on 25 Feb 20
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.
AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153
Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.
©2020 Shepard Technologies Private Limited. All Rights Reserved